Embera NeuroTherapeutics, a Sudbury, MA- and Shreveport, LA-based developer of drugs for treating addictions, has added another $4.5 million in Series A financing, the company announced today. The money comes from Embera’s existing backers, Louisiana Ventures, Louisiana Fund I, and Themelios Ventures, as well as other private investors. The funding will go to supporting the company’s drug, EMB-001, through a Phase 1 safety study, so it can advance in clinical trials as a treatment for nicotine dependence and cocaine addiction.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
